UY29176A1 - Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. - Google Patents

Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.

Info

Publication number
UY29176A1
UY29176A1 UY29176A UY29176A UY29176A1 UY 29176 A1 UY29176 A1 UY 29176A1 UY 29176 A UY29176 A UY 29176A UY 29176 A UY29176 A UY 29176A UY 29176 A1 UY29176 A1 UY 29176A1
Authority
UY
Uruguay
Prior art keywords
purinona
deazapurina
purina
compositions
contain
Prior art date
Application number
UY29176A
Other languages
English (en)
Inventor
Berdini Valerio
Saxty Gordon
Woodhead Steven John
Wyatt Paul Graham
Boyle Robert George
Walker David Winter
Collins Ian
John Caldwell
Tatiana Faria Da Fonseca
Original Assignee
Astex Therapeutics Ltd
Cancer Res Inst Royal
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35715573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29176(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0423655A external-priority patent/GB0423655D0/en
Application filed by Astex Therapeutics Ltd, Cancer Res Inst Royal, Cancer Rec Tech Ltd filed Critical Astex Therapeutics Ltd
Publication of UY29176A1 publication Critical patent/UY29176A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La invención proporciona un compuesto para su uso como inhibidor de la proteína quinasa B, siendo el compuesto un compuesto de fórmula (I): o sales, solvatos, tautómeros o N- oxidos del mismo, en donde T; J1- J2, E; Q1; G; R1 y R4 son como se definen en la memoria descriptiva y en las reivindicaciones.
UY29176A 2004-10-25 2005-10-24 Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos. UY29176A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62182104P 2004-10-25 2004-10-25
GB0423655A GB0423655D0 (en) 2004-10-25 2004-10-25 Pharmaceutical compounds
US68411905P 2005-05-24 2005-05-24

Publications (1)

Publication Number Publication Date
UY29176A1 true UY29176A1 (es) 2006-05-31

Family

ID=35715573

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29176A UY29176A1 (es) 2004-10-25 2005-10-24 Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.

Country Status (15)

Country Link
US (3) US8546407B2 (es)
EP (2) EP2272517B2 (es)
JP (1) JP5128284B2 (es)
AR (1) AR051342A1 (es)
AT (1) ATE513549T1 (es)
CY (1) CY1115946T1 (es)
DK (1) DK2272517T4 (es)
ES (1) ES2523266T5 (es)
HK (1) HK1110503A1 (es)
MY (1) MY179032A (es)
PL (1) PL2272517T5 (es)
PT (1) PT2272517E (es)
SI (1) SI2272517T2 (es)
UY (1) UY29176A1 (es)
WO (1) WO2006046024A1 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
RU2435769C2 (ru) * 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
DE102005037733A1 (de) * 2005-08-10 2007-02-15 Merck Patent Gmbh Adeninderivate
WO2007038215A1 (en) 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
EP2348023B9 (en) 2005-12-13 2017-03-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
WO2007084667A2 (en) * 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
WO2007125325A1 (en) * 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
US20090082370A1 (en) * 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
DK3421471T3 (da) * 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
EP2995619B1 (en) * 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007283401A1 (en) * 2006-08-09 2008-02-14 Merck Frosst Canada Ltd. Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme A delta-9 desaturase
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
AR064415A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
JP5492565B2 (ja) 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
WO2008121333A1 (en) * 2007-03-30 2008-10-09 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
EP2141994A4 (en) * 2007-04-26 2011-05-18 Avalon Pharmaceuticals POLYCYCLIC COMPOUNDS AND USES THEREOF
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
CN101932582B (zh) 2007-06-13 2013-09-25 因塞特公司 詹纳斯激酶抑制剂(R)-3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的盐
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
JP5479346B2 (ja) * 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑
UA101493C2 (ru) 2008-03-11 2013-04-10 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak
JP5575110B2 (ja) 2008-04-21 2014-08-20 レクシコン ファーマシューティカルズ インコーポレイテッド Ｌｉｍｋ２阻害剤、それらを含む組成物、及びそれらの使用の方法
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
MX2011005002A (es) 2008-11-11 2011-05-25 Lilly Co Eli Inhibidor de p70 s6 quinasa y terapia de combinacion de inhibidor del receptor de egfr.
CN102458581B (zh) 2009-05-22 2016-03-30 因塞特控股公司 作为JANUS激酶抑制剂的吡唑-4-基-吡咯并[2，3-d]嘧啶和吡咯-3-基-吡咯并[2，3-d]嘧啶的N-(杂)芳基-吡咯烷衍生物
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR20180126619A (ko) 2009-10-09 2018-11-27 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EA020151B1 (ru) 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
AU2010316780B2 (en) 2009-11-05 2015-07-16 Rhizen Pharmaceuticals Sa Novel benzopyran kinase modulators
ME02386B (me) 2010-03-10 2016-09-20 Incyte Holdings Corp Derivati piperidin-4-il azetidina kao inhibitori jak1
KR102303885B1 (ko) 2010-05-21 2021-09-24 인사이트 홀딩스 코포레이션 Ｊａｋ 저해제에 대한 국소 제형
WO2012037309A2 (en) * 2010-09-17 2012-03-22 Mallinckrodt Llc Improved process for the preparation of sufentanil base and related compounds
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9045485B2 (en) 2010-12-16 2015-06-02 Convergence Pharmaceuticals Limited ASK 1 inhibiting pyrrolopyrimidine derivatives
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
LT2694056T (lt) 2011-04-01 2019-12-10 Astrazeneca Ab Terapinis gydymas
MY168757A (en) 2011-05-04 2018-12-04 Rhizen Pharmaceuticals S A Novel compounds as modulators of protein kinases
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
KR101951220B1 (ko) 2011-07-13 2019-02-22 싸이토키네틱스, 인코포레이티드 조합 als 치료법
CA2844507A1 (en) 2011-08-10 2013-02-14 Novartis Pharma Ag Jak pi3k/mtor combination therapy
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
JP6309454B2 (ja) 2011-11-30 2018-04-11 アストラゼネカ アクチボラグ 癌の併用処置
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PL2870157T3 (pl) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektywne inhibitory pi3k delta
EA201590930A1 (ru) 2012-11-15 2015-08-31 Инсайт Корпорейшн Лекарственные формы руксолитиниба с замедленным высвобождением
JP6397831B2 (ja) 2013-03-06 2018-09-26 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤の製造方法及びその中間体
MY195091A (en) 2013-08-07 2023-01-10 Incyte Corp Sustained Release Dosage Forms for a JAK1 Inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
AU2016288230A1 (en) 2015-07-02 2018-01-25 Horizon Orphan Llc ADO-resistant cysteamine analogs and uses thereof
TW201726140A (zh) 2015-09-17 2017-08-01 瑞典商阿斯特捷利康公司 治療癌症之新型生物標記及方法
US11615297B2 (en) 2017-04-04 2023-03-28 Hailo Technologies Ltd. Structured weight based sparsity in an artificial neural network compiler
US11551028B2 (en) 2017-04-04 2023-01-10 Hailo Technologies Ltd. Structured weight based sparsity in an artificial neural network
US11238334B2 (en) 2017-04-04 2022-02-01 Hailo Technologies Ltd. System and method of input alignment for efficient vector operations in an artificial neural network
US11544545B2 (en) 2017-04-04 2023-01-03 Hailo Technologies Ltd. Structured activation based sparsity in an artificial neural network
US10387298B2 (en) 2017-04-04 2019-08-20 Hailo Technologies Ltd Artificial neural network incorporating emphasis and focus techniques
US11236086B2 (en) 2017-10-18 2022-02-01 Blueprint Medicines Corporation Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CR20200379A (es) 2018-01-30 2021-03-05 Incyte Corp Procesos e intermedio para elaborar un inhibidor de jak campo técnico
CA3095487A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
US11738026B2 (en) 2019-11-22 2023-08-29 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (es) 1963-04-04 1900-01-01
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
IT1252567B (it) 1991-12-20 1995-06-19 Italfarmaco Spa Derivati di 5-isochinolinsolfonammidi inibitori delle protein-chinasi
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0888349B1 (en) * 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
AU715202B2 (en) 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
US6187778B1 (en) 1997-08-05 2001-02-13 Pfizer Inc. 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
AP1411A (en) 1998-06-02 2005-05-10 Osi Pharm Inc Pyrrolo[2,3d] pyrimidine compositions and their use.
IL139811A0 (en) 1998-06-04 2002-02-10 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
HUP0102574A3 (en) 1998-06-19 2002-01-28 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CO5271715A1 (es) * 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
IL136458A0 (en) 2000-05-30 2001-06-14 Peptor Ltd Protein kinase inhibitors
MXPA03001777A (es) 2000-08-31 2003-06-04 Hoffmann La Roche Derivados de quinazolina como antagonistas adrenergicos alfa-1.
BR0115847A (pt) 2000-12-01 2004-02-25 Osi Pharm Inc Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1474425B9 (en) 2002-01-07 2008-07-02 Eisai Co., Ltd. Deazapurines and uses thereof
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1522314B1 (en) * 2002-06-26 2014-03-05 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2004043380A2 (en) 2002-11-08 2004-05-27 President And Fellows Of Harvard College Small technetium-99m and rhenium labeled agents and methods for imaging tissues, organs and tumors
MXPA05005983A (es) 2002-12-04 2005-08-18 Eisai Co Ltd Compuestos de anillo fusionado 1,3-dihidroimidazol.
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
SE0300457D0 (sv) 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
EP1601357A4 (en) 2003-03-10 2007-10-03 Schering Corp HETEROCYCLIC KINASE INHIBITORS: METHOD OF USE AND SYNTHESIS
CA2507893A1 (en) 2003-04-21 2004-11-04 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
FR2856685B1 (fr) 2003-06-25 2005-09-23 Merck Sante Sas Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AU2004268621C1 (en) 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1684694A2 (en) * 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
EP1698375B1 (en) * 2003-12-25 2014-04-02 Ono Pharmaceutical Co., Ltd. Azetidine ring compounds and drugs comprising the same
AU2005249380C1 (en) * 2004-04-23 2012-09-20 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
EP1848719B1 (en) 2004-12-28 2012-02-01 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
FR2880540B1 (fr) 2005-01-13 2008-07-11 Aventis Pharma Sa Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90
FR2880626B1 (fr) 2005-01-13 2008-04-18 Aventis Pharma Sa Derives de la purine, compositions les contenant et utilisation
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
US20090082370A1 (en) 2006-04-25 2009-03-26 Neil Thomas Thompson Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
DK3421471T3 (da) 2006-04-25 2021-06-14 Astex Therapeutics Ltd Purin- og deazapurinderivater som farmaceutiske forbindelser
EP2016077A2 (en) 2006-04-25 2009-01-21 Astex Therapeutics Limited Pharmaceutical compounds
JP2009534454A (ja) 2006-04-25 2009-09-24 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125325A1 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical compounds
AR064415A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
AR064416A1 (es) 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
TWI453021B (zh) 2007-10-11 2014-09-21 Astrazeneca Ab 新穎蛋白質激酶ｂ抑制劑

Also Published As

Publication number Publication date
SI2272517T1 (sl) 2015-01-30
EP2272517B1 (en) 2014-10-01
MY179032A (en) 2020-10-26
EP2272517A1 (en) 2011-01-12
EP1812004B1 (en) 2011-06-22
JP2008517984A (ja) 2008-05-29
US20090247538A1 (en) 2009-10-01
ATE513549T1 (de) 2011-07-15
PT2272517E (pt) 2014-12-04
US9006430B2 (en) 2015-04-14
ES2523266T3 (es) 2014-11-24
EP2272517B2 (en) 2017-09-20
US8809336B2 (en) 2014-08-19
US20140107137A1 (en) 2014-04-17
ES2523266T5 (es) 2017-12-29
PL2272517T5 (pl) 2018-04-30
WO2006046024A1 (en) 2006-05-04
HK1110503A1 (en) 2008-07-18
DK2272517T3 (da) 2014-10-27
AR051342A1 (es) 2007-01-03
EP1812004A1 (en) 2007-08-01
JP5128284B2 (ja) 2013-01-23
PL2272517T3 (pl) 2015-04-30
CY1115946T1 (el) 2017-01-25
US20140303177A1 (en) 2014-10-09
US8546407B2 (en) 2013-10-01
SI2272517T2 (sl) 2017-12-29
DK2272517T4 (da) 2017-11-27

Similar Documents

Publication Publication Date Title
UY29176A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen, métodos para su preparación y sus usos.
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
AR047917A1 (es) Derivados de 4-benzimidazol-2-il-piridazin-3-ona, preparacion de los mismos, y su empleo en medicamentos
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
ECSP088584A (es) Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl)
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
UY29437A1 (es) Nuevos antagonistas de cgrp
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
AR067505A1 (es) Derivados de pirimidinil-piridazinona
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
UY29198A1 (es) Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones
UY28763A1 (es) Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico
UY31468A1 (es) Derivados bis-(sulfonilamino) en terapia 065
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
UY28671A1 (es) Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CR11416A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
AR056860A1 (es) Derivados de triazol inhibidores de receptores de quinasa tgf-beta1, composiciones farmaceuticas que los contienen y usos para el tratamiento de tumores
ECSP066304A (es) Compuestos
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20180404